2 papers
stat.AP2025
Improving Maximum Tolerated Dose Selection in Model-Assisted Designs for Phase I Trials through Bayesian Dose-Response Model
Rentaro Wakayama, Tomotaka Momozaki, Shuji Ando
Model-assisted designs have garnered significant attention in recent years due to their high accuracy in identifying the maximum tolerated dose (MTD) and their operational simplici…
stat.AP2025
On window mean survival time with interval-censored data
Takuto Iijima, Tomotaka Momozaki, Shuji Ando
In recent years, cancer clinical trials have increasingly encountered non proportional hazards (NPH) scenarios, particularly with the emergence of immunotherapy. In randomized cont…